Elevation Oncology (ELEV)
(Real Time Quote from BATS)
$3.91 USD
+0.09 (2.36%)
Updated May 3, 2024 12:48 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Elevation Oncology, Inc. [ELEV]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Programs Expanding; New PT Up To $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Data in Mid-2024; Encouraging Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Clinical Program Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Developing an ADC For a Challenging Target; Initiate With Buy and a $1.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Partner Data Bolsters Outlook for EO-3021; Increasing PT to $6 (from $4)
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Initial Look at EO-3021 Ph 1 Data at ASCO; Promising Efficacy in Gastric Cancer
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Elevation Oncology, Inc.
Industry: Medical - Biomedical and Genetics
EO-3021 Oral Presentation at AACR; Partial Response in GI Cancer Case Study
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R